Over the past two decades, numerous complex cancer therapies called antibody drug conjugates (ADCs) have been tested in clinical trials and approved for use in patients. Investigators recently ...
Probody drug conjugates, immune-stimulating antibody conjugates, engineered toxin bodies, radioligand conjugates, and so on comprise the new wave of molecules in clinical development, seeking to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results